title: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.
abstract: A vaccine against human immunodeficiency virus (HIV) should induce virus-specific cytotoxic T lymphocyte (CTL) activity. Immunization of uninfected volunteers with a canarypox virus expressing HIV envelope was carried out in a phase I trial. Two injections of canarypox expressing HIV-1MN gp 160 (months 0 and 1) were followed by two boosts of recombinant envelope protein (months 3 and 6). HIV envelope-specific CTL were detected in peripheral blood mononuclear cells stimulated with autologous HIV-1-infected blast cells. T cell lines were obtained from 18 of 20 donors: CTL were detected at least once following immunization in 7 (39%) of these 18. This activity was mediated by major histocompatibility complex class I-restricted CD3+CD8+ T cells. For two subjects, this activity was still present 2 years after the initial immunization. The CTL responses with this prime-boost regimen are the best observed with any HIV vaccine tested in humans.
authors.affiliation: Unité de Virologie et Immunologie Cellulaire, Institut Pasteur, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Fleury
authors.forename: G
authors.initials: G
authors.lastname: Janvier
authors.forename: G
authors.initials: G
authors.lastname: Pialoux
authors.forename: F
authors.initials: F
authors.lastname: Buseyne
authors.forename: M N
authors.initials: MN
authors.lastname: Robertson
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: E
authors.initials: E
authors.lastname: Paoletti
authors.forename: M P
authors.initials: MP
authors.lastname: Kieny
authors.forename: J L
authors.initials: JL
authors.lastname: Excler
authors.forename: Y
authors.initials: Y
authors.lastname: Rivière
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D018150:Avipoxvirus / Q000235:genetics*; D017252:CD3 Complex / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D005260:Female; D019302:HIV Envelope Protein gp160 / Q000276:immunology*; D018023:HIV Seronegativity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D007156:Immunologic Memory; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D017252:CD3 Complex; D016827:CD8 Antigens; D019302:HIV Envelope Protein gp160; D015395:Histocompatibility Antigens Class I; D014614:Vaccines, Synthetic